Apollon Wealth Management LLC Lowers Position in Thermo Fisher Scientific Inc. $TMO

Apollon Wealth Management LLC cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 35.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,153 shares of the medical research company’s stock after selling 6,743 shares during the quarter. Apollon Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $4,928,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Fifth Third Wealth Advisors LLC lifted its stake in Thermo Fisher Scientific by 4.0% in the second quarter. Fifth Third Wealth Advisors LLC now owns 7,319 shares of the medical research company’s stock worth $2,968,000 after acquiring an additional 282 shares during the period. Conning Inc. boosted its holdings in shares of Thermo Fisher Scientific by 27.7% in the 2nd quarter. Conning Inc. now owns 13,132 shares of the medical research company’s stock valued at $5,325,000 after buying an additional 2,847 shares in the last quarter. Davis Rea LTD. boosted its holdings in shares of Thermo Fisher Scientific by 14.8% in the 2nd quarter. Davis Rea LTD. now owns 43,294 shares of the medical research company’s stock valued at $17,573,000 after buying an additional 5,582 shares in the last quarter. Blue Zone Wealth Advisors LLC grew its holdings in Thermo Fisher Scientific by 7.5% in the second quarter. Blue Zone Wealth Advisors LLC now owns 12,248 shares of the medical research company’s stock worth $4,966,000 after purchasing an additional 858 shares during the last quarter. Finally, JB Capital LLC grew its holdings in Thermo Fisher Scientific by 64.7% in the second quarter. JB Capital LLC now owns 11,903 shares of the medical research company’s stock worth $4,826,000 after purchasing an additional 4,676 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on TMO shares. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Robert W. Baird lifted their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday. Barclays increased their price objective on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Finally, Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $593.43.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $524.95 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company’s 50 day moving average is $488.68 and its 200 day moving average is $447.94. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market cap of $198.23 billion, a PE ratio of 30.36, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific’s quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.